HRTX Heron Therapeutics, Inc.
Healthcare$0.86-1.42%ClosedMarket Cap: $135.6M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
17.83
P/S
0.90
EV/EBITDA
-12.21
DCF Value
$-10.29
FCF Yield
-15.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.1%
Operating Margin
-6.9%
Net Margin
-20.5%
ROE
-1115.3%
ROA
-12.6%
ROIC
-6.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $34.7M | 69.4% | $-4.8M | $-8.1M | $— | — |
| Q4 null | $40.6M | 81.2% | $38.0K | $-3.0M | $— | — |
| FY null | $154.9M | 73.3% | $-2.5M | $-20.2M | $— | — |
| Q3 null | $38.2M | 59.7% | $-4.1M | $-17.5M | $— | — |
| Q2 null | $37.2M | 73.5% | $-1.6M | $-2.4M | $— | — |
| Q1 null | $38.9M | 78.3% | $3.2M | $2.6M | $— | — |
| Q4 null | $40.8M | 74.9% | $4.2M | $3.7M | $— | — |
| FY null | $144.3M | 73.2% | $-11.5M | $-13.6M | $— | — |
| Q3 null | $32.8M | 71.2% | $-4.5M | $-4.8M | $— | — |
| Q2 null | $36.0M | 70.8% | $-6.4M | $-9.2M | $— | — |
| Q1 null | $34.7M | 75.6% | $-4.8M | $-3.2M | $— | — |
| Q4 2023 | $34.2M | 71.1% | $-10.2M | $-10.7M | $-0.07 | — |